Lung Cancer
From the Journals
Lung cancer treatment combo may be effective after ICI failure
Phase 2 trial offers hope of a chemotherapy-free option for patients with advanced NSCLC.
Conference Coverage
The shifting sands of lung cancer screening
Studies find encouraging trends of stage shifting and minority screening, but more work remains.
From the Journals
New KRAS inhibitor shows promise in NSCLC
One out of three lung cancer patients previously treated with chemotherapy and immune therapy responded to a new targeted therapy.
Opinion
Drugging the undruggable
Targeted therapies are the ideal in drug development. New drugs that target KRAS (G12C) mutations mark a significant leap forward in oncology.
Opinion
Adjuvant vs. neoadjuvant? What has ASCO 2022 taught us regarding resectable NSCLC?
Phase 3 trials are needed to determine whether neoadjuvant chemo/immunotherapy outperforms adjuvant chemo/immunotherapy.
Conference Coverage
Promising treatment option for incurable lung cancer described as ‘significant’
Investigators suggest this combo should be standard therapy for NSCLC going forward.
Conference Coverage
Adagrasib shows durable benefit in KRAS-mutated NSCLC
“Our patients benefited clinically from this agent, and it appears to have improved overall survival.”
From the Journals
Immunotherapy treatment combo charts new course for resectable NSCLC treatment
Three cycles of neoadjuvant nivolumab plus chemotherapy improved long-term clinical outcomes in resectable stage IB-IIIA NSCLC.
Recap
Using Bronchoscopy to Optimize Targeted Therapy in Non-Small Cell Lung Cancer
The expanding treatment landscape in non–small cell lung cancer has deepened the collaboration...
From the Journals
Can lung cancer ID be as easy as breathing into an analyzer?
Breathomics testing is considered a promising lung cancer screening tool.